---
document_datetime: 2024-10-09 15:48:46
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/evenity-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: evenity-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.6776179
conversion_datetime: 2025-12-20 15:09:43.681399
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Evenity

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|-----------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10824 /202401  | Periodic Safety Update EU Single assessment - romosozumab | 05/09/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| R/0025               | Renewal of the marketing authorisation.                   | 27/06/2024                          | 22/08/2024                                  | SmPC, Annex II and PL            |                                   |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0024             | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS   | 16/05/2024   | n/a        |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| II/0023             | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                | 16/05/2024   | n/a        |                        |                                   |
| IB/0022             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                               | 19/12/2023   | n/a        |                        |                                   |
| IA/0021             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                | 30/10/2023   | n/a        |                        |                                   |
| PSUSA/10824 /202301 | Periodic Safety Update EU Single assessment - romosozumab                                                                                                                                                                                          | 31/08/2023   | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0020             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                     | 07/08/2023   | 22/08/2024 | SmPC, Labelling and PL |                                   |
| IB/0019             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                         | 19/06/2023   | n/a        |                        |                                   |
| N/0017              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                   | 22/02/2023   | 22/08/2024 | PL                     |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10824 /202207   | Periodic Safety Update EU Single assessment - romosozumab                                                                                                                                                                                                                                      | 09/02/2023   | n/a        |                  | PRAC Recommendation - maintenance   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------|-------------------------------------|
| IB/0016/G             | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.I.z - Quality change - Active substance - Other variation                                                                                                                    | 31/10/2022   | n/a        |                  |                                     |
| PSUSA/10824 /202201   | Periodic Safety Update EU Single assessment - romosozumab                                                                                                                                                                                                                                      | 01/09/2022   | n/a        |                  | PRAC Recommendation - maintenance   |
| IB/0014               | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                    | 17/05/2022   | n/a        |                  |                                     |
| II/0010               | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 07/04/2022   | n/a        |                  |                                     |
| PSUSA/10824 /202107   | Periodic Safety Update EU Single assessment - romosozumab                                                                                                                                                                                                                                      | 10/02/2022   | n/a        |                  | PRAC Recommendation - maintenance   |
| N/0012                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                               | 29/10/2021   | 22/08/2024 | Labelling and PL |                                     |

<div style=\"page-break-after: always\"></div>

| PSUSA/10824 /202101   | Periodic Safety Update EU Single assessment - romosozumab                                                                                                                  | 02/09/2021   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| PSUSA/10824 /202007   | Periodic Safety Update EU Single assessment - romosozumab                                                                                                                  | 11/02/2021   | n/a   | PRAC Recommendation - maintenance   |
| IA/0008               | B.II.d.2.e - Change in test procedure for the finished product - Update of the test procedure to comply with the updated general monograph in the Ph. Eur.                 | 11/12/2020   | n/a   |                                     |
| II/0005               | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                    | 15/10/2020   | n/a   |                                     |
| IB/0006               | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                 | 22/09/2020   | n/a   |                                     |
| PSUSA/10824 /202001   | Periodic Safety Update EU Single assessment - romosozumab                                                                                                                  | 03/09/2020   | n/a   | PRAC Recommendation - maintenance   |
| IB/0004               | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 25/06/2020   | n/a   |                                     |
| IB/0002               | B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation                                                                        | 13/03/2020   | n/a   |                                     |
| IB/0001               | B.IV.1.z - Change of a measuring or administration device - Other variation                                                                                                | 03/02/2020   | n/a   |                                     |